Charles Magness
Directeur/Bestuurslid bij Kineta One LLC
Vermogen: 397 064 $ op 30-04-2024
Profiel
Charles L.
Magness was the founder of Illumigen Biosciences, Inc. (founded in 2000), Kineta, Inc. (Washington) (founded in 2007), and Kineta, Inc. (founded in 2008), where he held the title of President & Chief Operating Officer, President & Chief Executive Officer, and President & Chief Executive Officer, respectively.
Currently, he is a Director at Kineta One LLC.
Magness's former positions include President, Chief Executive Officer & Director at KPI Therapeutics, Inc., Principal at the University of Washington, and Principal at McDonnell Douglas Automation.
He received a doctorate degree from Lehigh University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KINETA, INC.
5.66% | 31-12-2023 | 620 413 ( 5.66% ) | 397 064 $ | 30-04-2024 |
Actieve functies van Charles Magness
| Bedrijven | Functie | Begin |
|---|---|---|
Kineta One LLC
 Kineta One LLC Pharmaceuticals: MajorHealth Technology Kineta One LLC provides biotechnology services. The company is headquartered in Seattle, WA. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Charles Magness
| Bedrijven | Functie | Einde |
|---|---|---|
Illumigen Biosciences, Inc.
 Illumigen Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Illumigen Biosciences, Inc. provides pharmaceutical research services. It develops human genetic mutations that provide roadmap for therapeutic drug mechanisms. The company's product IB657 helps to investigate the cause of apparent immunity to HCV infection. Illumigen Biosciences was founded by Dr. Charles Magness and Shawn Iadonato in 2000 and is located in Seattle, WA | Oprichter | 01-01-2007 |
| KINETA, INC. | Algemeen Directeur | - |
KPI Therapeutics, Inc.
 KPI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KPI Therapeutics, Inc. operates as a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. It offers dalazatide, KPI-150, and KPI-190 for systemic autoimmune diseases including lupus; and CSP conopeptide for chronic pain. The company was founded in 2013 and is headquartered in Seattle, WA. | Algemeen Directeur | - |
| McDonnell Douglas Automation | Corporate Officer/Principal | - |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Opleiding van Charles Magness
| Lehigh University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| KINETA, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Kineta One LLC
Kineta One LLC Pharmaceuticals: MajorHealth Technology Kineta One LLC provides biotechnology services. The company is headquartered in Seattle, WA. | Health Technology |
Illumigen Biosciences, Inc.
Illumigen Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Illumigen Biosciences, Inc. provides pharmaceutical research services. It develops human genetic mutations that provide roadmap for therapeutic drug mechanisms. The company's product IB657 helps to investigate the cause of apparent immunity to HCV infection. Illumigen Biosciences was founded by Dr. Charles Magness and Shawn Iadonato in 2000 and is located in Seattle, WA | Health Technology |
| McDonnell Douglas Automation | |
Kineta, Inc. (Washington)
 Kineta, Inc. (Washington) Pharmaceuticals: MajorHealth Technology Kineta, Inc. engages in the development of novel immuno-therapies. It develops a pipeline of therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA. | Health Technology |
KPI Therapeutics, Inc.
KPI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KPI Therapeutics, Inc. operates as a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. It offers dalazatide, KPI-150, and KPI-190 for systemic autoimmune diseases including lupus; and CSP conopeptide for chronic pain. The company was founded in 2013 and is headquartered in Seattle, WA. | Health Technology |